Considerations for Ensuring Trial Continuity in the Wake of COVID-19

We’ve gathered questions from our customers and vendors regarding potential impact of COVID-19 on current and planned studies. Although we may not have answers for every situation, here are some areas that we are keenly focused on to support our sponsors:

• Talk to your CRO about CRA travel limitations and impact to on-site site qualification visits and investigator meetings.
• Assess the number of patients currently enrolled and unable to travel.
• Consider alternative monitoring strategies such as remote monitoring and centralized monitoring.
• Maintain communications with sites.
• Actively review and assess risk at the site level.
• Arrange to have investigational products (IP) shipped from pharmacy to home, if allowable under current regulations.
• Monitor your entire supply chain.
• Consider meetings with regulators, ethics committees, and IRB.
• Plan for any impact on business continuity and ensure employees are able to work virtually.
• Assess database lock impact to current studies.

For more information on Premier’s capabilities, click here.

Other Premier resources: https://premierresearch.cn/tag/covid-19/

Please visit the links below for more important information on COVID-19:

• EMA Guidance to Sponsors on How to Manage Clinical Trials During the COVID-19 Pandemic
• FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic
• MHRA Advice for Management of Clinical Trials in Relation to Coronavirus
• Seven Steps to Protect Yourself and Others from COVID-19
• ACRO’s Recommendations to Support Monitoring Oversight During COVID-19